Reduced expression of microRNA-130a promotes endothelial cell senescence and age-dependent impairment of neovascularization.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
26 05 2020
Historique:
received: 24 11 2019
accepted: 18 05 2020
pubmed: 28 5 2020
medline: 9 3 2021
entrez: 28 5 2020
Statut: ppublish

Résumé

Aging is associated with impaired neovascularization in response to ischemia. MicroRNAs are small noncoding RNAs emerging as key regulators of physiological and pathological processes. Here we investigated the potential role of microRNAs in endothelial cell senescence and age-dependent impairment of neovascularization. Next generation sequencing and qRT-PCR analyses identified miR-130a as a pro-angiogenic microRNA which expression is significantly reduced in old mouse aortic endothelial cells (ECs). Transfection of young ECs with a miR-130a inhibitor leads to accelerated senescence and reduced angiogenic functions. Conversely, forced expression of miR-130a in old ECs reduces senescence and improves angiogenesis. In a mouse model of hindlimb ischemia, intramuscular injection of miR-130a mimic in older mice restores blood flow recovery and vascular densities in ischemic muscles, improves mobility and reduces tissue damage. miR-130a directly targets antiangiogenic homeobox genes MEOX2 and HOXA5. MEOX2 and HOXA5 are significantly increased in the ischemic muscles of aging mice, but forced expression of miR-130a reduces the expression of these factors. miR-130a treatment after ischemia is also associated with increased number and improved functional activities of pro-angiogenic cells (PACs). Forced expression of miR-130a could constitute a novel strategy to improve blood flow recovery and reduce ischemia in older patients with ischemic vascular diseases.

Identifiants

pubmed: 32457253
doi: 10.18632/aging.103340
pii: 103340
pmc: PMC7346016
doi:

Substances chimiques

Homeodomain Proteins 0
Hoxa5 protein, mouse 0
MIRN130 microRNA, human 0
MIRN130 microRNA, mouse 0
Meox2 protein, mouse 0
MicroRNAs 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10180-10193

Subventions

Organisme : CIHR
ID : MOP-123490
Pays : Canada

Références

PLoS One. 2013 Jul 12;8(7):e68611
pubmed: 23874686
Blood. 2008 Feb 1;111(3):1217-26
pubmed: 17957028
N Engl J Med. 2003 Feb 13;348(7):593-600
pubmed: 12584367
Cardiovasc Res. 2008 Sep 1;79(4):581-8
pubmed: 18550634
Lymphat Res Biol. 2005;3(4):240-52
pubmed: 16379594
Trends Genet. 2011 Jun;27(6):233-41
pubmed: 21592610
Clin Exp Pharmacol Physiol. 2014 May;41(5):351-7
pubmed: 24750349
J Biol Chem. 2005 Mar 11;280(10):9330-5
pubmed: 15613470
Circulation. 2004 Jun 1;109(21):2487-91
pubmed: 15173038
Oncol Rep. 2015 Sep;34(3):1153-61
pubmed: 26134263
Circulation. 2002 Feb 5;105(5):608-13
pubmed: 11827927
Int J Biochem Cell Biol. 2015 Apr;61:129-37
pubmed: 25681685
Nat Rev Cardiol. 2013 Jul;10(7):387-96
pubmed: 23670612
Annu Rev Physiol. 1987;49:453-64
pubmed: 2436570
Science. 1997 Feb 14;275(5302):964-7
pubmed: 9020076
Circ Res. 2001 Jul 6;89(1):E1-7
pubmed: 11440984
Circ Res. 2002 May 31;90(10):E89-93
pubmed: 12039806
Circ Res. 2015 Apr 24;116(9):1561-78
pubmed: 25908729
Cancer Res. 2005 Feb 15;65(4):1414-24
pubmed: 15735029
N Engl J Med. 2005 Sep 8;353(10):999-1007
pubmed: 16148285
J Surg Res. 2003 May 1;111(1):91-9
pubmed: 12842453
Curr Opin Genet Dev. 2009 Jun;19(3):205-11
pubmed: 19446450
Circ Res. 2007 Jul 6;101(1):59-68
pubmed: 17540974
Cancer Res. 2017 Nov 15;77(22):6168-6178
pubmed: 28935812
PLoS One. 2010 May 20;5(5):e10724
pubmed: 20505758
J Clin Invest. 1998 Jun 1;101(11):2567-78
pubmed: 9616228
J Mol Cell Cardiol. 2015 Dec;89(Pt A):87-97
pubmed: 26458524
Arterioscler Thromb Vasc Biol. 2017 May;37(5):900-908
pubmed: 28254813
Circ Res. 1999 Aug 6;85(3):221-8
pubmed: 10436164
Circulation. 1999 Jan 5-12;99(1):111-20
pubmed: 9884387
Circ Res. 2009 Feb 27;104(4):442-54
pubmed: 19246688
Circ Res. 2004 Aug 20;95(4):343-53
pubmed: 15321944
Circ Res. 2012 Mar 30;110(7):1014-22
pubmed: 22461365
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2604-9
pubmed: 11226286
Mol Ther. 2018 Oct 3;26(10):2466-2475
pubmed: 30120059
Can J Physiol Pharmacol. 2017 Oct;95(10):1067-1077
pubmed: 28727928
Heart Vessels. 2000;15(4):176-80
pubmed: 11471657

Auteurs

Wahiba Dhahri (W)

Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Research Center Montréal, Montréal, Québec Canada.

Sylvie Dussault (S)

Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Research Center Montréal, Montréal, Québec Canada.

Éliane Légaré (É)

Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Research Center Montréal, Montréal, Québec Canada.

François Rivard (F)

Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Research Center Montréal, Montréal, Québec Canada.

Michel Desjarlais (M)

Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Research Center Montréal, Montréal, Québec Canada.

Raphael Mathieu (R)

Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Research Center Montréal, Montréal, Québec Canada.

Alain Rivard (A)

Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Research Center Montréal, Montréal, Québec Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH